Current diagnosis and treatment of polymyositis and dermatomyositis.

摘要: Idiopathic inflammatory myopathies (IIMs) are heterogeneous disorders that affect the skeletal muscles. Polymyositis, dermatomyositis, and inclusion body myositis major IIM subsets. Immune-mediated necrotizing myopathy became recognized as a potentially new subset. Since classification criteria published by International Myositis Classification Criteria Project have higher sensitivity specificity for subclassification than previous criteria, they should help precise diagnosis. It be noted several tests available in current clinical practice, such electromyography, magnetic resonance imaging, other myositis-specific autoantibodies anti-Jo-1 antibodies, were not included criteria. As treatment, glucocorticoids used empirically first-line treatment despite their various adverse effects. Concomitant with steroid-sparing immunosuppressive agents, including methotrexate, azathioprine, calcineurin inhibitors, mycophenolate mofetil, cyclophosphamide, reduces successfully initial glucocorticoid doses remission induction, relapse risk during tapering, effects of glucocorticoids. Treatment biologics, rituximab abatacept, seems promising some patients. Multi-target agents is effective refractory Considering proven efficacy tolerability multi-target patients autoimmune diseases, it good therapeutic option IIMs.